Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial

Por Colombo, N, McMeekin, D S, Schwartz, P E, Sessa, C, Gehrig, P A, Holloway, R, Braly, P, Matei, D, Morosky, A, Dodion, P F, Einstein, M H, Haluska, F
Publicado em 2013

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

Por Ott, P. A., Piha-Paul, S. A., Munster, P., Pishvaian, M. J., van Brummelen, E. M. J., Cohen, R. B., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., Simonelli, M., Morosky, A., Saraf, S., Emancipator, K., Koshiji, M., Bennouna, J.
Publicado no Ann Oncol (2017)